International Journal of Radiation Oncology * Biology * Physics
Volume 64, Issue 4 , Pages 983-994 , 15 March 2006

French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC)

Presented at the 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), Atlanta, GA, Oct 3–7, 2004.

  • René-Jean Bensadoun, M.D.

      Affiliations

    • Department of Radiation Oncology, Centre Antoine Lacassagne, Nice, France
    • Corresponding Author InformationReprint requests to: René-Jean Bensadoun, M.D., Centre Antoine Lacassagne, 33 avenue de Valombrose, 06189 Nice cedex 2, France. Tel: (+33) 4-9203-1270; Fax: (+33) 4-9203-1570
    • ,
  • Karen Bénézery, M.D.

      Affiliations

    • Department of Radiation Oncology, Centre Antoine Lacassagne, Nice, France
    • ,
  • Olivier Dassonville, M.D.

      Affiliations

    • Department of Head and Neck Surgery, Centre Antoine Lacassagne, Nice, France
    • ,
  • Nicolas Magné, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, Centre Antoine Lacassagne, Nice, France
    • ,
  • Gilles Poissonnet, M.D.

      Affiliations

    • Department of Head and Neck Surgery, Centre Antoine Lacassagne, Nice, France
    • ,
  • Alain Ramaïoli, M.D.

      Affiliations

    • Department of Statistics Unit, Centre Antoine Lacassagne, Nice, France
    • ,
  • Claire Lemanski, M.D.

      Affiliations

    • Centre Val d’Aurelle—Paul Lamarque, Montpellier, France
    • ,
  • Sylvain Bourdin, M.D.

      Affiliations

    • Centre René-Gauducheau, Nantes, France
    • ,
  • Jacques Tortochaux, M.D.

      Affiliations

    • Centre Jean-Perrin, Clermont-Ferrand, France
    • ,
  • Frédéric Peyrade, M.D.

      Affiliations

    • Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France
    • ,
  • Pierre-Yves Marcy, M.D.

      Affiliations

    • Department of Radiology, Centre Antoine Lacassagne, Nice, France
    • ,
  • Emmanuel Chamorey, Pharm.D.

      Affiliations

    • Department of Statistics Unit, Centre Antoine Lacassagne, Nice, France
    • ,
  • Jacques Vallicioni, M.D.

      Affiliations

    • Department of Head and Neck Surgery, Centre Antoine Lacassagne, Nice, France
    • ,
  • Hang Seng, M.D.

      Affiliations

    • Centre Henri-Becquerel, Rouen, France
    • ,
  • Claude Alzieu, M.D.

      Affiliations

    • Institut Paoli-Calmettes, Marseille, France
    • ,
  • Bernard Géry, M.D.

      Affiliations

    • Centre François-Baclesse, Caen, France
    • ,
  • Pierre Chauvel, M.D.

      Affiliations

    • Department of Radiation Oncology, Centre Antoine Lacassagne, Nice, France
    • ,
  • Maurice Schneider, M.D., Ph.D.

      Affiliations

    • Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France
    • ,
  • José Santini, M.D., Ph.D.

      Affiliations

    • Department of Otolaryngology, University Hospital, Nice, France
    • ,
  • François Demard, M.D., Ph.D.

      Affiliations

    • Department of Head and Neck Surgery, Centre Antoine Lacassagne, Nice, France
    • ,
  • Gilles Calais, M.D., Ph.D.

      Affiliations

    • Hôpital Jean Bretonneau, Tours, France

Received 6 May 2005 ,Revised 20 September 2005 ,Accepted 27 September 2005.

References 

  1. Vokes EE , Weichselbaum RR , Lippman SM , Hong WK . Head and neck cancer . N Engl J Med . 1993;328:184–194
  2. Horiot JC , Le Fur R , NGuyen T , et al.   Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma (Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy) . Radiother Oncol . 1992;25:231–241
  3. Brizel DM , Albers ME , Fisher SR , et al.   Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer . N Engl J Med . 1998;18:1798–1804
  4. Budach V , Stuschke M , Budach W , et al.   Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer (Final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 prospective randomized trial) . J Clin Oncol . 2005;23:1125–1135
  5. Calais G , Alfonsi M , Bardet E , et al.   Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma . J Natl Cancer Inst . 1999;91:2081–2086
  6. Hehr T , Classen J , Schreck U , et al.   Hyperfractionated accelerated radiotherapy alone and with concomitant chemotherapy to the head and neck (Treated within and outside of randomized clinical trials) . Int J Radiat Oncol Biol Phys . 2004;58:1424–1430
  7. Pignon JP , Bourhis J , Domenge C , Designé L . Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma (Three meta-analyses of updated individual data) . Lancet . 2000;355:949–955
  8. Bensadoun RJ , Etienne MC , Dassonville O , et al.   Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx (Clinical and pharmacological data of a French multicenter phase II study) . Int J Radiat Oncol Biol Phys . 1998;42:237–245
  9. Bourhis J , Etessami A , Wibault P , et al.   Altered fractionation radiotherapy in the management of head and neck carcinomas (Advantages and limitations) . Curr Opin Oncol . 2004;16:215–219
  10. Al-Sarraf M . Cisplatin combinations in the treatment of head and neck cancer . J Clin Oncol . 1994;21:28–34
  11. Bensadoun RJ , Franquin JC , Ciais G , et al.   Low-energy He/Ne laser in the prevention of radiation-induced mucositis (A multicenter phase III randomized study in patients with head and neck cancer) . Support Care Cancer . 1999;7:244–252
  12. Cowen D , Tardieu C , Schubert M , et al.   Low energy helium-neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant (Results of a double blind randomized trial) . Int J Radiat Oncol Biol Phys . 1997;38:697–703
  13. Fu KK , Pajak TF , Trotti A , et al.   Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas (First report of RTOG 9003) . Int J Radiat Oncol Biol Phys . 2000;48:7–16
  14. Pinto LH , Canary PC , Araujo CM , et al.   Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in Stages III and IV oropharyngeal carcinoma . Int J Radiat Oncol Biol Phys . 1991;21:557–562
  15. Allal AS , Taussy D , Mach N , et al.   Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience . Int J Radiat Oncol Biol Phys . 2004;58:1431–1436
  16. Parsons JT , Mendenhall WM , Stringer SP , et al.   Twice-a-day radiotherapy for squamous cell carcinoma of the head and neck (The University of Florida experience) . Head Neck . 1993;15:87–96
  17. Garden AS , Morrison WH , Ang KK , et al.   Hyperfractionated radiation in the treatment of squamous cell carcinomas of the head and neck (A comparison of two fractionation schedules) . Int J Radiat Oncol Biol Phys . 1995;31:493–502
  18. Griffiths GO , Parmar MK , Bailey AJ . A prospective quality of life in the CHART randomized trial in head and neck cancer (Short-term and long-term patient reported symptoms. CHART Steering Committee. Continuous hyperfractionated accelerated radiotherapy) . Br J Cancer . 1999;81:1196–1205
  19. Hammerlid E , Persson LO , Sullivan M , et al.   Quality of life effects of psychosocial intervention in patients with head and neck cancer . Otolaryngol Head Neck Surg . 1999;120:507–516
  20. Dimery I , Hong W . Overview of combined modality therapies for head and neck cancer . J Natl Cancer Inst . 1993;85:95–111
  21. Garden A . Is there still a role for induction chemotherapy for head and neck cancer? . J Clin Oncol . 2005;23:1059–1060
  22. Rooney M , Kish J , Jacobs J , et al.   Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120 hour 5FU infusion and Cisplatin . Cancer . 1985;55:1123–1128
  23. Thyss A , Schneider M , Santini J , et al.   Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck . Br J Cancer . 1986;54:755–760
  24. Vokes EE , Schilsky RL , Weichselbaum RR , et al.   Induction chemotherapy with cisplatin, fluorouracil, and high dose leucovorin for locally advanced head and neck cancer (A clinical and pharmacologic analysis) . J Clin Oncol . 1990;8:241–247
  25. Lo TC , Wiley AL , Ansfield FJ , et al.   Combined radiotherapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx (A randomized study) . Am J Roentgenol . 1976;126:229–235
  26. Jeremic B , Shibamoto Y , Milicic B , et al.   Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck (A prospective randomized trial) . J Clin Oncol . 2000;18:1458–1464
  27. Adelstein DJ , Kalish LA , Adams GL , et al.   Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer (An Eastern Cooperative Oncology Group Pilot Study) . J Clin Oncol . 1993;11:2136–2142
  28. Pignon JP , Baujat B , Bourhis J . Apport des méta-analyses sur données individuelles au traitement des cancers ORL . Cancer Radiothérapie . 2005;9:31–36
  29. Abitbol AA , Sridhar KS , Lewin AA , et al.   Hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and mitomycin-c (+/- granulocyte-colony stimulating factor) in the treatment of patients with locally advanced head and neck carcinoma . Cancer . 1997;80:266–276
  30. Denham JW , Abbot RL . Concurrent cisplatin, infusional fluorouracil, and conventionally fractionated radiation therapy in head and neck cancer (Dose-limiting mucosal toxicity) . J Clin Oncol . 1991;9:458–463
  31. Wendt TG , Grabenbauer GG , Rödel CM , et al.   Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer (A randomized multicenter study) . J Clin Oncol . 1998;16:1318–1324
  32. Bensadoun RJ , Magné N , Marcy PY , Demard F . Chemotherapy- and radiotherapy-induced mucositis in head and neck cancer patients (New trends in pathophysiology, prevention and treatment) . Eur Arch Otorhinolaryngol . 2001;258:481–487
  33. Magné N , Marcy PY , Foa C , et al.   Comparison between nasogastric tube feeding and percutaneous fluoroscopic gastrostomy in advanced head and neck cancer patients . Eur Arch Otorhinolaryngol . 2001;258:89–92
  34. Allen AM , Worden F , Dawson LA , et al.   Feeding tube placement facilitates aggressive hyperfractionated chemoradiation (HXCRT) for unresectable head and neck cancer . Int J Radiat Oncol Biol Phys . 2004;601:S510–S511
  35. Kallman R . The importance of schedule and drug dose intensity in combinations of modalities . Int J Radiat Oncol Biol Phys . 1994;28:761–771
  36. Schneider M , Etienne MC , Milano G , et al.   Phase II trial of cisplatin, fluorouracil, and pure l folinic acid for locally advanced head and neck cancer (A pharmacokinetic and clinical survey) . J Clin Oncol . 1995;13:1656–1662
  37. Chambers MS , Garden AS , Rosenthal D , et al.   Intensity-modulated radiotherapy (Is xerostomia still prevalent?) . Curr Oncol Rep . 2005;7:131–136
  38. Magné N , Marcy PY , Chamorey E , et al.   Concomitant twice-a-day radiotherapy and chemotherapy in unresectable head and neck cancer patients (A long-term quality of life analysis) . Head Neck . 2001;23:678–682
  39. Maguire PD , Meyerson MB , Neal CR , et al.   Toxic cure (Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community) . Int J Radiat Oncol Biol Phys . 2004;58:698–704
  40. Brizel DM , Prosnotz RG , Hunter S , et al.   Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer . Int J Radiat Oncol Biol Phys . 2004;58:1418–1423
  41. Chambers MS , Garden AS , Kies MS , Martin JW . Radiation-induced xerostomia in patients with head and neck cancer (Pathogenesis, impact on quality of life, and management) . Head Neck . 2004;26:796–807
  42. Oh HK , Chambers MS , Garden AS , et al.   Risk of osteoradionecrosis after extraction of impacted third molars in irradiated head and neck cancer patients . J Oral Maxillofac Surg . 2004;62:139–144
  43. Denis F , Garaud P , Bardet E , et al.   Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma (Comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems) . Int J Radiat Oncol Biol Phys . 2003;55:93–98
  44. Garden AS , Asper JA , Morrison WH , et al.   Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma? . Cancer . 2004;100:1171–1178
  45. Selek U , Garden AS , Morrison WH , et al.   Radiation therapy for early-stage carcinoma of the oropharynx . Int J Radiat Oncol Biol Phys . 2004;59:743–751
  46. Dassonville O , Formento JL , Francoual M , et al.   Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer . J Clin Oncol . 1993;11:1873–1878
  47. Magné N , Pivot X , Bensadoun RJ , et al.   Radiochemotherapy of unresectable pharyngeal cancer (Prognostic impact of the epidermal growth factor receptor levels) . Eur J Cancer . 2001;37:2169–2177
  48. Shin DM , Donato NJ , Perez-Soler R , et al.   Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer . Clin Cancer Res . 2001;7:1204–1213
  49. Soulieres D , Senzer NN , Vokes EE , et al.   Multicentric phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck . J Clin Oncol . 2004;22:77–85
  50. Magné N , Fischel JL , Dubreuil A , et al.   Sequence-dependent effects of ZD1839 (‘Iressa’) in combination with cytotoxic treatment in human head and neck cancer . Br J Cancer . 2002;86:819–827

 The French “Fédération Nationale des Centres de Lutte Contre le Cancer” (FNCLCC) promoted the present study in relation with the “Groupe d’Oncologie Radiothérapie Tête et Cou” (GORTEC).

PII: S0360-3016(05)02712-4

doi: 10.1016/j.ijrobp.2005.09.041

International Journal of Radiation Oncology * Biology * Physics
Volume 64, Issue 4 , Pages 983-994 , 15 March 2006

Article Tools

* Image Usage & Resolution